Group Dialectical Behavior Therapy as add-on Treatment for Adults With Attention Deficit/Hyperactive Disorder
Randomized Clinical Trial With Adapted Skill Training Group From Dialectical Behavior Therapy as add-on Treatment for Adults With Attention Deficit/Hyperactive Using Medication
2 other identifiers
interventional
31
1 country
1
Brief Summary
Attention-Deficit/Hyperactive Disorder (ADHD) in adults is associated with global impairments and deficits in quality of life. The ADHD functional impairments during adulthood usually persist even after adequate medication treatment. The Skill Training Group of the Dialectical Behavioral Therapy (DBT) is one of the group therapies that had been adapted for the specific treatment of ADHD patients. Our primary aim is to explore the feasibility of the approach in different culture and to evaluate the efficacy of the Skill Training Group as an add-on treatment for adults using ADHD medication. This is a Randomized Clinical Trial comparing the Skill Training Group added to stimulants to treatment as usual. 52 adults previously diagnosed with ADHD and treated with stimulants in our ADHD outpatient program will be enrolled. Only patients with residual symptoms will be included (ADHD-Self Report Scale - ASRS ≥ 20). The intervention comprises the standard 12 sessions therapy program. The groups will have between 8 and 12 patients each, and will be conducted by a trained DBT therapist with supervision from a senior DBT therapist. The primary outcome will be the ASRS scores. Secondary outcomes include scores in ADHD Quality of Life, Beck's Depression Inventory, Beck's Anxiety Inventory, and performance in a neuropsychological test (difference between pre and post-intervention) (Stop Signal Task). Adherence to the protocol will also be checked. The recruitment was initially scheduled for beginning in November.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Apr 2018
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 9, 2017
CompletedFirst Posted
Study publicly available on registry
October 31, 2017
CompletedStudy Start
First participant enrolled
April 7, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 24, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
March 27, 2019
CompletedFebruary 17, 2020
February 1, 2020
8 months
October 9, 2017
February 14, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in Adult Attention-Deficit/Hyperactive Disorder Self Rating Scale
Sefl rated scale to measure Attention Deficit Hyperactive Disorder Symptoms Symptoms. ASRS has 18 questions about ADHD symptoms. Each question is scored between 0 (never happen), and 4 (very frequently). The total score goes from 0 up to 72. Higher scores mean more symptoms and higher ADHD's impairments.
12 Weeks
Secondary Outcomes (11)
Change in Attention-Deficit/Hyperactive Disorder Self Rating Scale - Mid-treatment
6 Weeks
Change in Attention-Deficit/Hyperactive Disorder Quality of Life
12 Weeks
Change in Attention-Deficit/Hyperactive Disorder Quality of Life - Mid-treatment
6 weeks
Change in Beck Depression Inventory
12 Weeks
Change in Beck Depression Inventory - Mid-treatment
6 Weeks
- +6 more secondary outcomes
Study Arms (2)
Skill Training Group
EXPERIMENTALA twelve sessions protocol of the Skill Training Group of the Dialectical Behavior Therapy.
Treatment as Usual
ACTIVE COMPARATORPatients will have one psychiatric session to control their medication adherence.
Interventions
A 12 session version of the Skill Training Group of the Dialectical Behavior Therapy, adapted for treatment of ADHD.
Conventional protocol using only medication (including drug adherence).
Eligibility Criteria
You may qualify if:
- Patients with ADHD
- Medicated with following drugs and minimum daily dosages:
- Methylphenidate ≥ 0.5 mg/kg Lisdexamfetamine ≥ 30mg Bupropion ≥ 150 mg Modafinil ≥ 200mg Imipramine ≥ 1mg/kg
- At least one month of stabilized dosage for any psychiatric medication.
- ADHD-Self Report Scale ≥ 20.
- Knowledge of oral and written communication in Portuguese
- IQ\>85 (intelligence quotient)
You may not qualify if:
- diagnoses of Borderline or Anti-social personality disorders.
- diagnoses of autism spectrum disorder
- current episode of major depression or suicide toughs
- current episodes of mania or hypomania
- recent episodes of drug abuse (last 6 months)
- diagnoses of drug dependence
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Centro de Pesquisa Clínica
Porto Alegre, Rio Grande do Sul, 90035-903, Brazil
Related Publications (1)
Moritz GR, Pizutti LT, Cancian ACM, Dillenburg MS, de Souza LAS, Lewgoy LB, Basso P, Andreola MMP, Bau CHD, Victor MM, Teche SP, Grevet EH, Philipsen A, Rohde LAP. Feasibility trial of the dialectical behavior therapy skills training group as add-on treatment for adults with attention-deficit/hyperactivity disorder. J Clin Psychol. 2021 Mar;77(3):516-524. doi: 10.1002/jclp.23049. Epub 2020 Sep 2.
PMID: 32880953DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Luis Augusto Rohde
UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL (UFRGS)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 9, 2017
First Posted
October 31, 2017
Study Start
April 7, 2018
Primary Completion
November 24, 2018
Study Completion
March 27, 2019
Last Updated
February 17, 2020
Record last verified: 2020-02
Data Sharing
- IPD Sharing
- Will not share
Patient's individual data will be available only for the researchers and additional members of the research team, and for the patients it self.